123I‐metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders
Identifieur interne : 000268 ( France/Analysis ); précédent : 000267; suivant : 000269123I‐metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders
Auteurs : Olivier Rascol [France] ; Ludwig Schelosky [Suisse]Source :
- Movement Disorders [ 0885-3185 ] ; 2009.
English descriptors
- KwdEn :
- 3-Iodobenzylguanidine (diagnostic use), Autonomic Nervous System Diseases (etiology), Autonomic Nervous System Diseases (radionuclide imaging), Heart (physiopathology), Heart (radionuclide imaging), Humans, Lewy Body Disease (complications), Lewy Body Disease (radionuclide imaging), MIBG scintigraphy, MSA, Parkinson Disease (radionuclide imaging), Parkinson's disease, Parkinsonian Disorders (radionuclide imaging), Radiopharmaceuticals (diagnostic use), autonomic nervous system, cardiac sympathetic innervation, differential diagnosis.
- MESH :
- chemical , diagnostic use : 3-Iodobenzylguanidine, Radiopharmaceuticals.
- complications : Lewy Body Disease.
- etiology : Autonomic Nervous System Diseases.
- physiopathology : Heart.
- radionuclide imaging : Autonomic Nervous System Diseases, Heart, Lewy Body Disease, Parkinson Disease, Parkinsonian Disorders.
- Humans.
Abstract
Autonomic dysfunction is common in Lewy body disorders (Parkinson's disease, Dementia with Lewy Bodies, Pure Autonomic Failure, and REM sleep disorder). The loss of post‐ganglionic myocardial sympathetic nerve fibers is a prominent feature of autonomic dysfunction in such disorders. 123I‐metaiodobenzylguanidine (MIBG) scintigraphy that visualizes catecholaminergic terminals in vivo is a biomarker used to detect cardiac sympathetic degeneration. Abnormal MIBG uptake has been consistently reported in Lewy body disorders. Some studies agree in the notion that increasing bradykinesia is related with an incremental cardiac sympathetic denervation, whereas tremor is not closely linked to cardiac denervation. “Atypical” parkinsonian syndromes, including Multiple System Atrophy, Progressive Supranuclear Palsy, and others, show modest reductions of cardial MIBG uptake. MIBG scintigraphy is moderately sensitive and specific in differentiating Parkinson's disease from such syndromes. Conversely, its sensitivity and specificity might be better in cognitively impaired patients, helping differential diagnosis between Dementia with Lewy Bodies, and Alzheimer disease. Confounding factors (comorbidities, comedications) should be carefully controlled before analyzing MIBG scintigraphy. © 2009 Movement Disorder Society
Url:
DOI: 10.1002/mds.22499
Affiliations:
- France, Suisse
- Midi-Pyrénées
- Toulouse
- Université Toulouse III - Paul Sabatier, Université de Toulouse
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000A47
- to stream Istex, to step Curation: 000A47
- to stream Istex, to step Checkpoint: 001088
- to stream PubMed, to step Corpus: 001B24
- to stream PubMed, to step Curation: 001B24
- to stream PubMed, to step Checkpoint: 001F89
- to stream Ncbi, to step Merge: 002859
- to stream Ncbi, to step Curation: 002859
- to stream Ncbi, to step Checkpoint: 002859
- to stream Main, to step Merge: 002D47
- to stream Main, to step Curation: 002486
- to stream Main, to step Exploration: 002486
- to stream France, to step Extraction: 000268
Links to Exploration step
ISTEX:F0E4F24A5977047882DC9362028C31CB5E425B21Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">123I‐metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders</title><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><country>France</country><placeName><settlement type="city">Toulouse</settlement><region type="region" nuts="2">Midi-Pyrénées</region></placeName><orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName><orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName></affiliation></author><author><name sortKey="Schelosky, Ludwig" sort="Schelosky, Ludwig" uniqKey="Schelosky L" first="Ludwig" last="Schelosky">Ludwig Schelosky</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:F0E4F24A5977047882DC9362028C31CB5E425B21</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/mds.22499</idno><idno type="url">https://api.istex.fr/document/F0E4F24A5977047882DC9362028C31CB5E425B21/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000A47</idno><idno type="wicri:Area/Istex/Curation">000A47</idno><idno type="wicri:Area/Istex/Checkpoint">001088</idno><idno type="wicri:doubleKey">0885-3185:2009:Rascol O:i:metaiodobenzylguanidine:scintigraphy</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:19877202</idno><idno type="wicri:Area/PubMed/Corpus">001B24</idno><idno type="wicri:Area/PubMed/Curation">001B24</idno><idno type="wicri:Area/PubMed/Checkpoint">001F89</idno><idno type="wicri:Area/Ncbi/Merge">002859</idno><idno type="wicri:Area/Ncbi/Curation">002859</idno><idno type="wicri:Area/Ncbi/Checkpoint">002859</idno><idno type="wicri:Area/Main/Merge">002D47</idno><idno type="wicri:Area/Main/Curation">002486</idno><idno type="wicri:Area/Main/Exploration">002486</idno><idno type="wicri:Area/France/Extraction">000268</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">123I‐metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders</title><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>INSERM CIC‐P302 and UMR‐825, Departments of Clinical Pharmacology and Neurosciences, CHU and University UPS of Toulouse, Toulouse</wicri:regionArea><placeName><settlement type="city">Toulouse</settlement></placeName><placeName><settlement type="city">Toulouse</settlement><region type="region" nuts="2">Midi-Pyrénées</region></placeName><orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName><orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName></affiliation></author><author><name sortKey="Schelosky, Ludwig" sort="Schelosky, Ludwig" uniqKey="Schelosky L" first="Ludwig" last="Schelosky">Ludwig Schelosky</name><affiliation wicri:level="1"><country xml:lang="fr">Suisse</country><wicri:regionArea>Neurologie und klinische Neurophysiologie, Kantonsspital Münsterlingen, Münsterlingen</wicri:regionArea><wicri:noRegion>Münsterlingen</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009">2009</date><biblScope unit="vol">24</biblScope><biblScope unit="issue">S2</biblScope><biblScope unit="page" from="S732">S732</biblScope><biblScope unit="page" to="S741">S741</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">F0E4F24A5977047882DC9362028C31CB5E425B21</idno><idno type="DOI">10.1002/mds.22499</idno><idno type="ArticleID">MDS22499</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>3-Iodobenzylguanidine (diagnostic use)</term><term>Autonomic Nervous System Diseases (etiology)</term><term>Autonomic Nervous System Diseases (radionuclide imaging)</term><term>Heart (physiopathology)</term><term>Heart (radionuclide imaging)</term><term>Humans</term><term>Lewy Body Disease (complications)</term><term>Lewy Body Disease (radionuclide imaging)</term><term>MIBG scintigraphy</term><term>MSA</term><term>Parkinson Disease (radionuclide imaging)</term><term>Parkinson's disease</term><term>Parkinsonian Disorders (radionuclide imaging)</term><term>Radiopharmaceuticals (diagnostic use)</term><term>autonomic nervous system</term><term>cardiac sympathetic innervation</term><term>differential diagnosis</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>3-Iodobenzylguanidine</term><term>Radiopharmaceuticals</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Lewy Body Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Autonomic Nervous System Diseases</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Heart</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Autonomic Nervous System Diseases</term><term>Heart</term><term>Lewy Body Disease</term><term>Parkinson Disease</term><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Autonomic dysfunction is common in Lewy body disorders (Parkinson's disease, Dementia with Lewy Bodies, Pure Autonomic Failure, and REM sleep disorder). The loss of post‐ganglionic myocardial sympathetic nerve fibers is a prominent feature of autonomic dysfunction in such disorders. 123I‐metaiodobenzylguanidine (MIBG) scintigraphy that visualizes catecholaminergic terminals in vivo is a biomarker used to detect cardiac sympathetic degeneration. Abnormal MIBG uptake has been consistently reported in Lewy body disorders. Some studies agree in the notion that increasing bradykinesia is related with an incremental cardiac sympathetic denervation, whereas tremor is not closely linked to cardiac denervation. “Atypical” parkinsonian syndromes, including Multiple System Atrophy, Progressive Supranuclear Palsy, and others, show modest reductions of cardial MIBG uptake. MIBG scintigraphy is moderately sensitive and specific in differentiating Parkinson's disease from such syndromes. Conversely, its sensitivity and specificity might be better in cognitively impaired patients, helping differential diagnosis between Dementia with Lewy Bodies, and Alzheimer disease. Confounding factors (comorbidities, comedications) should be carefully controlled before analyzing MIBG scintigraphy. © 2009 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>France</li><li>Suisse</li></country><region><li>Midi-Pyrénées</li></region><settlement><li>Toulouse</li></settlement><orgName><li>Université Toulouse III - Paul Sabatier</li><li>Université de Toulouse</li></orgName></list><tree><country name="France"><noRegion><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name></noRegion></country><country name="Suisse"><noRegion><name sortKey="Schelosky, Ludwig" sort="Schelosky, Ludwig" uniqKey="Schelosky L" first="Ludwig" last="Schelosky">Ludwig Schelosky</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000268 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000268 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= France
|étape= Analysis
|type= RBID
|clé= ISTEX:F0E4F24A5977047882DC9362028C31CB5E425B21
|texte= 123I‐metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders
}}
| This area was generated with Dilib version V0.6.23. |  |